Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

Khanh Do, Giovanna Speranza, Lun Ching Chang, Eric Polley, Rachel Bishop, Weimin Zhu, Jane B. Trepel, Sunmin Lee, Min Jung Lee, Robert J. Kinders, Larry Phillips, Jerry Collins, John Lyons, Woondong Jeong, Ramya Antony, Alice P. Chen, Len Neckers, James H. Doroshow, Shivaani Kummar

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Inhibition of heat shock 90 (Hsp90) molecular chaperones allows targeting of multiple proteins involved in tumorigenesis. We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week) in a phase I trial. This study followed an accelerated titration design with a starting dose of 20 mg/m2/dose and a standard 3+3 dose escalation design for dose level 4 (120 mg/m2/dose) and above. Additional patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array analysis. Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/week schedule. Common toxicities were gastrointestinal, hepatic, and hematologic. Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T1/2 ∼8 h). No responses were observed; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles. Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs. Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression. Further combination studies are needed in order to target prospective driver oncoproteins.

Original languageEnglish (US)
Pages (from-to)921-930
Number of pages10
JournalInvestigational New Drugs
Volume33
Issue number4
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

HSP90 Heat-Shock Proteins
Appointments and Schedules
Neoplasms
Pharmacokinetics
Biopsy
Protein Array Analysis
Proteins
Molecular Chaperones
Oncogene Proteins
Protein Transport
Cluster Analysis
Shock
Carcinogenesis
Up-Regulation
Hot Temperature
(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone
Safety
Liver

Keywords

  • Hsp27 heat-shock proteins
  • Hsp70 heat-shock proteins
  • Hsp90 inhibitor
  • Molecular chaperones
  • Proteolysis

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. / Do, Khanh; Speranza, Giovanna; Chang, Lun Ching; Polley, Eric; Bishop, Rachel; Zhu, Weimin; Trepel, Jane B.; Lee, Sunmin; Lee, Min Jung; Kinders, Robert J.; Phillips, Larry; Collins, Jerry; Lyons, John; Jeong, Woondong; Antony, Ramya; Chen, Alice P.; Neckers, Len; Doroshow, James H.; Kummar, Shivaani.

In: Investigational New Drugs, Vol. 33, No. 4, 01.08.2015, p. 921-930.

Research output: Contribution to journalArticle

Do, K, Speranza, G, Chang, LC, Polley, E, Bishop, R, Zhu, W, Trepel, JB, Lee, S, Lee, MJ, Kinders, RJ, Phillips, L, Collins, J, Lyons, J, Jeong, W, Antony, R, Chen, AP, Neckers, L, Doroshow, JH & Kummar, S 2015, 'Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors', Investigational New Drugs, vol. 33, no. 4, pp. 921-930. https://doi.org/10.1007/s10637-015-0255-1
Do, Khanh ; Speranza, Giovanna ; Chang, Lun Ching ; Polley, Eric ; Bishop, Rachel ; Zhu, Weimin ; Trepel, Jane B. ; Lee, Sunmin ; Lee, Min Jung ; Kinders, Robert J. ; Phillips, Larry ; Collins, Jerry ; Lyons, John ; Jeong, Woondong ; Antony, Ramya ; Chen, Alice P. ; Neckers, Len ; Doroshow, James H. ; Kummar, Shivaani. / Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. In: Investigational New Drugs. 2015 ; Vol. 33, No. 4. pp. 921-930.
@article{c71da651e2064e5fab2a7c63990edff7,
title = "Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors",
abstract = "Inhibition of heat shock 90 (Hsp90) molecular chaperones allows targeting of multiple proteins involved in tumorigenesis. We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week) in a phase I trial. This study followed an accelerated titration design with a starting dose of 20 mg/m2/dose and a standard 3+3 dose escalation design for dose level 4 (120 mg/m2/dose) and above. Additional patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array analysis. Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/week schedule. Common toxicities were gastrointestinal, hepatic, and hematologic. Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T1/2 ∼8 h). No responses were observed; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles. Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs. Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression. Further combination studies are needed in order to target prospective driver oncoproteins.",
keywords = "Hsp27 heat-shock proteins, Hsp70 heat-shock proteins, Hsp90 inhibitor, Molecular chaperones, Proteolysis",
author = "Khanh Do and Giovanna Speranza and Chang, {Lun Ching} and Eric Polley and Rachel Bishop and Weimin Zhu and Trepel, {Jane B.} and Sunmin Lee and Lee, {Min Jung} and Kinders, {Robert J.} and Larry Phillips and Jerry Collins and John Lyons and Woondong Jeong and Ramya Antony and Chen, {Alice P.} and Len Neckers and Doroshow, {James H.} and Shivaani Kummar",
year = "2015",
month = "8",
day = "1",
doi = "10.1007/s10637-015-0255-1",
language = "English (US)",
volume = "33",
pages = "921--930",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

AU - Do, Khanh

AU - Speranza, Giovanna

AU - Chang, Lun Ching

AU - Polley, Eric

AU - Bishop, Rachel

AU - Zhu, Weimin

AU - Trepel, Jane B.

AU - Lee, Sunmin

AU - Lee, Min Jung

AU - Kinders, Robert J.

AU - Phillips, Larry

AU - Collins, Jerry

AU - Lyons, John

AU - Jeong, Woondong

AU - Antony, Ramya

AU - Chen, Alice P.

AU - Neckers, Len

AU - Doroshow, James H.

AU - Kummar, Shivaani

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Inhibition of heat shock 90 (Hsp90) molecular chaperones allows targeting of multiple proteins involved in tumorigenesis. We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week) in a phase I trial. This study followed an accelerated titration design with a starting dose of 20 mg/m2/dose and a standard 3+3 dose escalation design for dose level 4 (120 mg/m2/dose) and above. Additional patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array analysis. Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/week schedule. Common toxicities were gastrointestinal, hepatic, and hematologic. Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T1/2 ∼8 h). No responses were observed; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles. Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs. Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression. Further combination studies are needed in order to target prospective driver oncoproteins.

AB - Inhibition of heat shock 90 (Hsp90) molecular chaperones allows targeting of multiple proteins involved in tumorigenesis. We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week) in a phase I trial. This study followed an accelerated titration design with a starting dose of 20 mg/m2/dose and a standard 3+3 dose escalation design for dose level 4 (120 mg/m2/dose) and above. Additional patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array analysis. Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/week schedule. Common toxicities were gastrointestinal, hepatic, and hematologic. Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T1/2 ∼8 h). No responses were observed; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles. Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs. Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression. Further combination studies are needed in order to target prospective driver oncoproteins.

KW - Hsp27 heat-shock proteins

KW - Hsp70 heat-shock proteins

KW - Hsp90 inhibitor

KW - Molecular chaperones

KW - Proteolysis

UR - http://www.scopus.com/inward/record.url?scp=84943586558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943586558&partnerID=8YFLogxK

U2 - 10.1007/s10637-015-0255-1

DO - 10.1007/s10637-015-0255-1

M3 - Article

C2 - 26082332

AN - SCOPUS:84943586558

VL - 33

SP - 921

EP - 930

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -